Back to top

Analyst Blog

Emergent BioSolutions (EBS - Analyst Report) announced that the U.S. Food and Drug Administration (FDA) has awarded orphan drug designation to its vaccine BioThrax for the post-exposure prophylaxis (PEP) of anthrax resulting from exposure (suspected or confirmed) to bacillus anthracis.

We note that BioThrax is the sole vaccine to be cleared by the FDA for the pre-exposure prophylaxis of anthrax disease. Emergent BioSolutions is looking to get BioThrax approved for the PEP indication in combination with antibiotics for treating patients with suspected or confirmed exposure to anthrax spores.

The FDA’s decision to grant orphan status to BioThrax for the PEP will provide multiple incentives to the company on the vaccine’s development costs for the indication. The designation is granted by the FDA to indications being developed to treat/prevent rare diseases (affecting less than 200,000 people in the U.S.) having significant unmet medical needs. Moreover, the status makes the drug eligible for seven years of marketing exclusivity in the U.S. following approval for the orphan indication.

Emergent BioSolutions intends to seek FDA approval for the vaccine’s expanded indication on the basis of data from the recently completed non-interference study in the final quarter of 2014. Emergent BioSolutions will not be required to pay the fees for the filing of the supplemental biologics license application (sBLA) as a result of orphan status granted by the U.S. regulatory body.

Before the submission, the company will hold a meeting with the U.S. regulatory body next month. The FDA designation will facilitate discussions according to the company. We expect investor focus to remain on updates regarding Emergent BioSolutions’ efforts to expand BioThrax’s label.

Emergent BioSolutions carries a Zacks Rank #3 (Hold).  Better-ranked stocks in the medical sector include Regeneron Pharmaceuticals (REGN - Analyst Report), Amgen (AMGN - Analyst Report) and Alexion Pharmaceuticals (ALXN - Analyst Report). While Regeneron and Amgen carry a Zacks Rank #1 (Strong Buy), Alexion holds a Zacks Rank #2 (Buy).

Read the Full Research Report on EBS
Read the Full Research Report on ALXN
Read the Full Research Report on REGN
Read the Full Research Report on AMGN

Zacks Investment Research

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CENTURY ALU… CENX 22.53 +4.50%
ERBA DIAGNO… ERB 2.91 +4.30%
PLANAR SYST… PLNR 4.31 +3.86%
MALLINCKROD… MNK 72.17 +3.83%
GTT COMMUNI… GTT 12.06 +3.52%